Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 9 de 9
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Br J Cancer ; 101(8): 1393-401, 2009 Oct 20.
Article de Anglais | MEDLINE | ID: mdl-19773754

RÉSUMÉ

BACKGROUND: Classical Hodgkin's lymphoma (cHL), although a malignant disease, has many features in common with an inflammatory condition. The aim of this study was to establish the molecular characteristics of the two most common cHL subtypes, nodular sclerosis (NS) and mixed cellularity (MC), based on molecular profiling and immunohistochemistry, with special reference to the inflammatory microenvironment. METHODS: We analysed 44 gene expression profiles of cHL whole tumour tissues, 25 cases of NS and 19 cases of MC, using Affymetrix chip technology and immunohistochemistry. RESULTS: In the NS subtype, 152 genes showed a significantly higher expression, including genes involved in extracellular matrix (ECM) remodelling and ECM deposition similar to wound healing. Among these were SPARC, CTSK and COLI. Immunohistochemistry revealed that the NS-related genes were mainly expressed by macrophages and fibroblasts. Fifty-three genes had a higher expression in the MC subtype, including several inflammation-related genes, such as C1Qalpha, C1Qbeta and CXCL9. In MC tissues, the C1Q subunits were mainly expressed by infiltrating macrophages. CONCLUSIONS AND INTERPRETATIONS: We suggest that the identified subtype-specific genes could reflect different phases of wound healing. Our study underlines the potential function of infiltrating macrophages in shaping the cHL tumour microenvironment.


Sujet(s)
Analyse de profil d'expression de gènes , Maladie de Hodgkin/classification , Maladie de Hodgkin/anatomopathologie , Inflammation/anatomopathologie , Cicatrisation de plaie , Adolescent , Adulte , Sujet âgé , Marqueurs biologiques , Matrice extracellulaire/métabolisme , Femelle , Fibrose , Maladie de Hodgkin/génétique , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen
2.
Hum Pathol ; 32(9): 963-9, 2001 Sep.
Article de Anglais | MEDLINE | ID: mdl-11567226

RÉSUMÉ

The tumor necrosis factor receptor-associated factor 1 (TRAF1) participates in the signal transduction of various members of the tumor necrosis factor receptor (TNFR) family, including TNFR2, CD40, CD30, and the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1). In vitro, TRAF1 is induced by LMP1, and previous studies have suggested that expression of TRAF1 is higher in EBV-associated tumors than in their EBV-negative counterparts. To determine whether this was the case in posttransplant lymphoproliferative disease (PTLD) and related disorders, we used immunohistochemistry to analyze expression of TRAF1 in a total of 42 such lesions arising in a variety of immunosuppressive states. The specimens consisted of 22 PTLD lesions, 18 acquired immunodeficiency syndrome-associated lymphomas, including 6 primary central nervous system lymphomas, and 2 cases of Hodgkin disease. The presence of latent EBV infection was determined by EBER in situ hybridization, and expression of EBV-LMP1 was detected by immunohistochemistry. Latent EBV infection, as determined by a positive EBER signal, was detected in 36 of 42 tumors. Of the EBER-positive specimens, 30 of 36 also expressed LMP1. Twenty-four of 30 LMP1-positive tumors, including both Hodgkin disease specimens, expressed TRAF1, compared with only 3 of 12 LMP1-negative tumors. This difference was statistically significant (P <.005). These results show frequent expression of TRAF1 at the protein level in LMP1-positive PTLD and related disorders and suggest an important role for LMP1-mediated TRAF1 signaling in the pathogenesis of EBV-positive tumors arising in immunosuppressive states.


Sujet(s)
Lymphome lié au SIDA/métabolisme , Syndromes lymphoprolifératifs/métabolisme , Transplantation d'organe , Protéines/métabolisme , Protéines ribosomiques , Protéines de la matrice virale/métabolisme , Infections à virus Epstein-Barr/complications , Infections à virus Epstein-Barr/métabolisme , Infections à virus Epstein-Barr/anatomopathologie , Herpèsvirus humain de type 4/génétique , Herpèsvirus humain de type 4/isolement et purification , Humains , Techniques immunoenzymatiques , Hybridation in situ , Lymphome lié au SIDA/anatomopathologie , Lymphome lié au SIDA/virologie , Syndromes lymphoprolifératifs/anatomopathologie , Syndromes lymphoprolifératifs/virologie , Complications postopératoires , Protéines de liaison à l'ARN/analyse , Facteur-1 associé aux récepteurs de TNF
3.
J Pathol ; 194(2): 158-64, 2001 Jun.
Article de Anglais | MEDLINE | ID: mdl-11400143

RÉSUMÉ

The tumour necrosis factor receptor-associated factors (TRAFs) 1 and 2 participate in the signal transduction of various members of the tumour necrosis factor receptor (TNFR) family, including TNFR1, TNFR2, CD40, CD30, and the Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP1). Previous in situ hybridization studies have demonstrated TRAF1 transcripts in the malignant cells of the majority of Hodgkin's disease (HD) tumours, where the expression of TRAF1 was higher in EBV-associated tumours than in their EBV-negative counterparts. In order to determine whether TRAF1 and also TRAF2 were expressed at the protein level in HD and whether there was any relationship to EBV status, immunohistochemistry has been used to detect these proteins in a series of HD specimens. TRAF1 protein was detected more frequently in Hodgkin/Reed-Sternberg (HRS) cells from EBV-positive tumours than in their EBV-negative counterparts. This difference was statistically significant (p=0.01). In contrast, TRAF2 expression by HRS cells appeared to be independent of EBV status. Using a sequential labelling approach, co-localization of LMP1 with either TRAF1 or TRAF2 was also demonstrated in HRS cells from EBV-positive tumours.


Sujet(s)
Infections à virus Epstein-Barr/métabolisme , Maladie de Hodgkin/métabolisme , Maladie de Hodgkin/virologie , Protéines/analyse , Cellules de Reed-Sternberg/composition chimique , Technique de Western/méthodes , Femelle , Humains , Immunohistochimie/méthodes , Hybridation in situ , Mâle , Facteur-1 associé aux récepteurs de TNF , Facteur-2 associé aux récepteurs de TNF , Protéines de la matrice virale/analyse , Latence virale
4.
Mol Pathol ; 53(3): 145-9, 2000 Jun.
Article de Anglais | MEDLINE | ID: mdl-10897334

RÉSUMÉ

BACKGROUND: In vitro the Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP-1) has been shown to upregulate expression of matrix metalloproteinase 9 (MMP-9), a member of a family of zinc dependent endopeptidases that is believed to facilitate tumour invasion and metastasis by degradation of the extracellular matrix. AIM: To test whether the expression of MMP-9 in Hodgkin's disease correlates with EBV status and survival and to investigate whether LMP-1 expression affects MMP-9 concentrations in the Hodgkin's disease cell line, L428. METHODS: MMP-9 expression was measured by means of immunohistochemistry in a series of Hodgkin's disease tumours and this expression was correlated with EBV status and survival. The influence of LMP-1 on MMP-9 expression was also investigated in the Hodgkin's disease cell line, L428. RESULTS: MMP-9 expression was demonstrated in the malignant Hodgkin and Reed-Sternberg cells of all (n = 86) formalin fixed, paraffin wax embedded Hodgkin's disease tumours examined. Although the intensity of MMP-9 immunostaining varied between cases, there was no correlation between MMP-9 expression and EBV status or survival. MMP-9 expression was also detected in a variety of non-malignant cells, including fibroblasts. MMP-9 was detected by zymography in the L428 and KMH2 Hodgkin's disease cell lines, whereas low or undetectable amounts of MMP-9 were found in the L591 Hodgkin's disease cell line. Induction of LMP-1 expression in the Hodgkin's disease cell line L428 did not result in a detectable increase in the values of MMP-9 as measured by zymography. CONCLUSIONS: These results demonstrate that MMP-9 is consistently expressed by the Hodgkin and Reed-Sternberg cells of Hodgkin's disease tumours and by the Hodgkin's disease cell lines, L428 and KMH2. However, this expression does not appear to be related either to LMP-1 values or to survival.


Sujet(s)
Marqueurs biologiques tumoraux/métabolisme , Herpèsvirus humain de type 4/isolement et purification , Maladie de Hodgkin/enzymologie , Matrix metalloproteinase 9/métabolisme , Technique de Western , Maladie de Hodgkin/virologie , Humains , Techniques immunoenzymatiques , Taux de survie , Cellules cancéreuses en culture , Protéines de la matrice virale/métabolisme
5.
Leuk Res ; 23(8): 741-9, 1999 Aug.
Article de Anglais | MEDLINE | ID: mdl-10456672

RÉSUMÉ

Acute myeloid leukaemia (AML) is a heterogeneous malignant disease in which disease progression at the level of CD34 positive cells has a major impact in drug resistance and relapse. The multi-drug resistance (MDR1) gene product, P-glycoprotein is expressed mainly in CD34 positive AML cells and Bcl-2 is expressed simultaneously with several putative drug resistance parameters in these cells. Bcl-2 over-expression is associated with CD34 positivity, poor response to chemotherapy and reduced overall survival in AML patients. Recently, all-trans retinoic acid (RA) has been reported to enhance cytarabine-induced apoptosis and downregulate Bcl-2 in several human myeloid leukaemia CD34 negative cells. The two CD34 positive human myeloid leukaemia cell lines: KG1 and KGla have the unique feature of expressing significant functional P-glycoprotein. Thus, the efficacy of RA in enhancing cytrabine- and fludarabine-induced apoptosis and overcoming the resistance was examined in both KG1 (CD34+CD7-) and KGla (CD34+CD7+) human myeloid leukaemia cells in the present study. Both cytarabine and fludarabine induced a dose dependent increase in the number of apoptotic cells in both CD34 positive cell types. Interestingly, the cytarabine-induced apoptosis was significantly more than fludarabine-induced apoptosis in both cell types. All-trans RA alone failed to induce apoptosis or inhibit proliferation of either of the two human CD34 positive leukaemia cell types. However, RA enhanced cytarabine- or fludarabine-induced apoptosis and inhibition of proliferation in KG1 CD34+CD7- but not in KGla CD34+CD7+ myeloid leukaemia cells. As single agents, RA, cytarabine and fludarabine reduced Bcl-2 expression in a dose dependent manner in both cell types. Using a quantitative ELISA assay, the Bcl-2 protein concentration was reduced by 86 or 100%, after 72 h of treatment with 10 microM cytarabine or fludarabine, respectively, in both CD34 positive leukaemia cell types. The addition of RA to cytarabine enhanced its induced reduction of Bcl-2 in KG1 CD34+CD7- but not in KGla CD34+CD7+ human myeloid leukaemia cells. Meanwhile, RA failed to augment fludarabine-induced reduction of Bcl-2 in both cell types. In conclusion, the present results suggest a potential role for the combination of RA and cytarabine in the treatment of refractory and/or relapsed AML patients with CD34+CD7- but not CD34+CD7+ blast cells.


Sujet(s)
Antigènes CD34/immunologie , Antimétabolites antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Leucémie myéloïde/métabolisme , Protéines proto-oncogènes c-bcl-2/métabolisme , Trétinoïne/pharmacologie , Cytarabine/pharmacologie , Humains , Leucémie myéloïde/immunologie , Leucémie myéloïde/anatomopathologie , Cellules cancéreuses en culture , Vidarabine/analogues et dérivés , Vidarabine/pharmacologie
6.
Mol Pathol ; 52(1): 1-10, 1999 Feb.
Article de Anglais | MEDLINE | ID: mdl-10439832

RÉSUMÉ

Since its initial description over twenty years ago the PCR has become one of the most valuable and flexible tools available to biomedical research. Subsequently, refinements and modifications to the basic approach, many of which have been described in this review, have enabled the application of the PCR to many areas of diagnostic medicine and have ensured its rapid acceptance as a routine test in many pathology disciplines. The growing importance of molecular approaches to the diagnosis of disease, particularly in histopathology, will continue to secure an ever expanding role for the PCR in diagnostic pathology.


Sujet(s)
Réaction de polymérisation en chaîne/méthodes , ADN/isolement et purification , Analyse de mutations d'ADN/méthodes , Humains , RT-PCR/méthodes , Analyse de séquence d'ADN/méthodes
7.
Mol Pathol ; 52(6): 307-22, 1999 Dec.
Article de Anglais | MEDLINE | ID: mdl-10748864

RÉSUMÉ

The Epstein-Barr virus (EBV) has been linked to the development of a variety of human malignancies, including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, some T cell lymphomas, post-transplant lymphoproliferative disease, and more recently, certain cancers of the stomach and smooth muscle. This review summarizes these associations and in particular the role of the viral latent genes in the transformation process.


Sujet(s)
Infections à virus Epstein-Barr/complications , Tumeurs/virologie , Transformation cellulaire néoplasique , Transformation cellulaire virale , Herpèsvirus humain de type 4/physiologie , Humains , Lymphomes/virologie , Latence virale/génétique
8.
Mol Pathol ; 52(3): 135-9, 1999 Jun.
Article de Anglais | MEDLINE | ID: mdl-10621834

RÉSUMÉ

AIMS: Previous studies documenting hyperprolactinaemia in patients with colorectal cancer have suggested that the tumour is the source of hormone production. The aim of this study was to determine the frequency of hyperprolactinaemia in patients with colorectal cancer before, during, and after surgery, and also to determine whether prolactin is produced by these tumours. METHODS: Serum prolactin concentrations were measured in 20 patients with colorectal cancer before, during, and after surgical resection of their tumours. Samples taken during surgery included peripheral venous blood and blood taken from the main veins draining the tumour. To determine whether the tumour was responsible for the production of prolactin in these patients, paraffin wax embedded sections of tumour specimens were subjected to immunohistochemistry and western blotting using a monoclonal antibody to prolactin. RESULTS: Five patients (three women, two men) had preoperative prolactin concentrations above the normal reference range, although this increase was of clinical importance in only two. After surgical resection of their tumours, prolactin concentrations remained high in both patients. All 20 patients had greatly raised prolactin values at the time of surgery, irrespective of whether this was measured in peripheral blood or in blood taken from veins draining the tumour. All 20 colorectal cancer tissue samples, including those with raised preoperative and/or postoperative prolactin concentrations, were negative for prolactin staining. Frozen tissue was also available in four cases. The absence of prolactin gene expression in these four tumours was confirmed both by repeat immunohistochemistry and by western blotting. A further 50 colorectal cancer cases examined by immunohistochemistry alone were also unreactive for prolactin. CONCLUSIONS: The results of this study suggest that serum prolactin concentrations may occasionally be raised in colorectal cancer patients, but that the tumour is not the source of hormone production.


Sujet(s)
Tumeurs colorectales/métabolisme , Protéines tumorales/biosynthèse , Prolactine/biosynthèse , Technique de Western , Tumeurs colorectales/sang , Tumeurs colorectales/chirurgie , Femelle , Expression des gènes , Humains , Techniques immunoenzymatiques , Mâle , Protéines tumorales/sang , Protéines tumorales/génétique , Prolactine/sang , Prolactine/génétique
9.
Anal Biochem ; 263(2): 189-97, 1998 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-9799531

RÉSUMÉ

Mannitol oxidase (manox) is an H2O2-generating oxidase apparently unique to molluscs and especially abundant in alimentary tissues. In the digestive gland it is localized to an organelle ("mannosome") that forms an unusual tubular membrane system. We have developed a novel centrifugation procedure for >100-fold purification of these membranes in 20% yield from approximately 30 g of digestive gland of the slug Arion ater. Mannosomes from several other gastropod species are also substantially purified by the procedure. Four successive density gradient separations are employed which minimize structural damage by exploiting near isosmotic conditions early on and by completely avoiding traumatic pelleting and resuspension. Plasma membrane contamination is reduced by digitonin-induced density perturbation. The purified preparation is characterized by a predominant 68-kDa integral membrane protein and retains the in situ appearance of hexagonally arranged tubules with an enveloping outer membrane.


Sujet(s)
Système digestif/ultrastructure , Mollusca/anatomie et histologie , Animaux , Système digestif/métabolisme , Électrophorèse sur gel de polyacrylamide , Protéines membranaires/isolement et purification , Microscopie électronique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE